UK Migraine Drugs Market Report 2022 to 2030

UK Migraine Drugs Market Analysis

$ 3999

UK migraine drugs market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. High alcohol consumption, rising healthcare costs, rising job stress, and rising medicine demand are all expected to drive market expansion. In the years ahead, it is anticipated that there will be a rise in public knowledge of migraines and available treatments which will further act as a driver for Migraine Drugs Market. The major key players in this market are Amgen, Abbott Laboratories, Allergan, Eli Lilly, Pfizer, Inc., AstraZeneca, Johnson and Johnson Services, Inc., and GlaxoSmithKline.

ID: IN10GBPH337 CATEGORY: Pharmaceuticals GEOGRAPHY: UK AUTHOR: Saloni Shah

Buy Now

UK Migraine Drugs Market Analysis Summary

UK Migraine Drugs Market is valued at around $137.6 Mn in 2022 and is projected to reach $234.4 Mn by 2030, exhibiting a CAGR of 6.89% during the forecast period 2023-2030.

A migraine is a headache that often affects one side of the head and can be extremely painful, throbbing, or pulsating. It frequently comes with high sensitivity to light and sound as well as nausea and vomiting. The pain from a migraine attack can be so intense that it interferes with your regular activities and can persist for hours or even days. A warning sign known as an aura may appear before or concurrently with the headache in some persons. Auras can include speech difficulties, tingling on one side of the face or in an arm or leg, and vision problems like light flashes or blind spots. Although the exact causes of migraines are unknown, genetics and environmental factors seem to be involved. A significant pain pathway, the trigeminal nerve, and its interactions with the brainstem may play a role. The same may be said for chemical imbalances in the brain, such as serotonin, which helps your nervous system control pain. Serotonin's involvement in migraines is being researched. Other neurotransmitters, such as calcitonin gene-related peptides, also contribute to migraine pain (CGRP). High alcohol consumption, rising healthcare costs, rising job stress, and rising medicine demand are all expected to drive market expansion. In the years ahead, it is anticipated that there would be a rise in public knowledge of migraines and available treatments which will further act as a driver for Migraine Drugs Market. The major key players in this market are Amgen, Abbott Laboratories, Allergan, Eli Lilly, Pfizer, Inc., AstraZeneca, Johnson and Johnson Services, Inc., and GlaxoSmithKline.

Market Dynamics

Market Growth Drivers

In the upcoming years, it is predicted that increased sedentary lifestyles among the younger population will increase the prevalence of neurological illnesses like migraine. For instance, nearly a billion people worldwide experience migraine attacks, according to the Migraine Research Foundation. According to the Foundation, this neurological disorder affects nearly 39 million people in the United States alone.

Market Restraints

However, there is little public awareness of migraine, and it is predicted that the lack of knowledge in developing countries on how to treat the condition effectively will restrain market growth. Moreover, the high cost associated with the treatment of migraine may hamper the market growth.

Competitive Landscape

Key Players

Amgen
Abbott Laboratories
Allergan
Eli Lilly
Pfizer, Inc.
AstraZeneca
Johnson and Johnson Services, Inc.
GlaxoSmithKline

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

UK Migraine Drugs Market Segmentation

By Drug Class

Preventative Treatment
Ergotamine
Analgesics
Triptans
Acute Treatment
Calcium Channel Blockers
Beta-Blockers
Anti-Convulsants
Anti-depressants
Anti-serotonergic Drugs
Others

By Route Of Administration

Oral
Injectable
Others

By Distribution Channel

Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.